VIRX

Viracta Therapeutics, Inc.

A precision oncology company that developed medicines for cancers tied to the Epstein-Barr virus (EBV). Its "kick-and-kill" therapy, combining the drug nanatinostat with the antiviral valganciclovir, worked to wake dormant viruses inside cancer cells so the immune system could destroy them. The name blends "virus" with "activation," and the company was co-founded in 2015 by oncologist Dr. Ivor Royston, an early figure in the biotech industry.